PTGS2 and hepatocellular carcinoma: Cyclooxygenase-2 (COX-2) and telomerase reverse-transcriptase (TERT) were prioritized because both are well-validated drivers of hepatocellular carcinoma: COX-2 is over-expressed in HepG2 and other HCC cell lines, where its inhibition suppresses proliferation, angiogenesis and immune evasion [101,102], while activating TERT-promoter mutations and high telomerase activity occur in ≈ 60% of HCC tumors and in HepG2 cells, sustaining replicative immortality and poor prognosis [103,104].